pharmaceuticals
- Repeal of LIFO (last in, first out) - Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP) (H.R. 1920); ASP, generally (in the context of Deficit Reduction)
- Legislation to exclude cancer drugs from sequestration cuts; Cancer Care Payment Reform Act (H.R. 1834/S. 463) - Legislation to prevent and reduce prescription drug abuse
- Legislation to prohibit prescription drug plan sponsors and MA-PD organizations under Medicare from retroactively reducing payment on clean claims submitted by pharmacies
- Pharmaceutical compounding and implementation of the Drug Quality Security Act
- Issues related to drug pricing, including the Improving Access to Affordable Prescription Drug Act (H.R. 1776/S. 771)
- Issues related to the importation of prescription medicines, including the Affordable and Safe Prescription Drug Importation Act (H.R. 1245/S. 469)
TAX - Taxation/Internal Revenue Code MMM - Medicare/Medicaid PHA - Pharmacy
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
900 G Street NW, Suite 301, Washington, DC, 20001, US
VINCENT A. ROBERTI, SR. STEVEN E IRIZARRY ISRAEL S KLEIN STEVEN E IRIZARRY VINCENT A. ROBERTI, SR. ISRAEL S KLEIN STEVEN E IRIZARRY VINCENT A. ROBERTI, SR. ISRAEL S KLEIN